Neovasc to Report Fourth Quarter and Fiscal Year 2020 Results on March 11, 2021
Neovasc Inc. (NVCN) will release its fourth quarter and fiscal year 2020 results on March 11, 2021, after market close. CEO Fred Colen and CFO Chris Clark will host a conference call at 4:30 PM EST to discuss the results. The company specializes in cardiovascular medical devices, including the Neovasc Reducer™ for refractory angina and Tiara™ for mitral valve disease treatment, currently under investigation. The Reducer has been available in Europe since 2015 but is not commercially available in the U.S. Interested investors can join the call via a dial-in number or webcast.
- Neovasc is a leader in cardiovascular medical device technology.
- The Neovasc Reducer™ has been available in Europe since 2015.
- Upcoming conference call to discuss financial results may provide insights into future growth.
- Neovasc Reducer™ is not commercially available in the U.S.
- Tiara™ is still under clinical investigation, causing potential delays in revenue generation.
VANCOUVER and MINNEAPOLIS, March 04, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (NASDAQ, TSX: NVCN) will report results for the fourth quarter and fiscal year ended December 31, 2020 after the market close on Thursday, March 11, 2021. Neovasc President and Chief Executive Officer Fred Colen and Chief Financial Officer Chris Clark will host a conference call to review the Company’s results at 4:30 pm EST.
Interested parties may access the conference call by dialing (877) 407-9208 or (201) 493-6784 (International). Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Neovasc website at https://www.neovasc.com/investors/.
A replay of the webcast will be available approximately 30 minutes after the conclusion of the call using the link on the Neovasc website.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. The Company is a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina. Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently commercially available in the United States (2 U.S. patients have been treated under Compassionate Use) and has been commercially available in Europe since 2015, and Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com.
Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.646.877.9641
Mike.Cavanaugh@westwicke.com
Media
Sean Leous
Westwicke/ICR
Phone: +1.646.677.1839
Sean.Leous@icrinc.com
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words "expect", "anticipate", "estimate", "may", "will", "should", "intend," "believe", and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to the expansion of its product range and the growing cardiovascular marketplace. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances. Many factors could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including those described in the "Risk Factors" section of the Company's Annual Report on Form 20-F and in the Management's Discussion and Analysis for the three and nine months ended September 30, 2020 (copies of which may be obtained at www.sedar.com or www.sec.gov). These factors should be considered carefully, and readers should not place undue reliance on the Company's forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
When will Neovasc release its Q4 and fiscal year 2020 results?
What is the ticker symbol for Neovasc?
Who will host the Neovasc earnings call?
How can I access the Neovasc conference call?
What products does Neovasc develop?
